

CIDARA THERAPEUTICS, INC.

Reported by

DAVARPANAH NICOLE NEGAR

FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 05/12/25 for the Period Ending 05/01/25

Address	6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO, CA, 92121
Telephone	858-752-6170
CIK	0001610618
SIC Code	2836 - Biological Products, (No Diagnostic Substances)
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Davarpanah Nicole Negar (Last) (First) (Middle) 6310 NANCY RIDGE DRIVE, SUITE 101 (Street) SAN DIEGO, CA 92121 (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol Cidara Therapeutics, Inc. [CDTX]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chief Medical Officer				
			3. Date of Earliest Transaction (MM/DD/YYYY) 5/1/2025									
			4. If Amendment, Date Original Filed (MM/DD/YYYY)					6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price	Title	Amount or Number of Shares			
Common Stock	5/1/2025		A		10,000 ⁽¹⁾	A	\$0	Common Stock	20,000	31,692	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (right to buy)	\$21.75	5/1/2025		A		20,000		⁽²⁾	4/30/2035	Common Stock	20,000	\$0	20,000	D		

Explanation of Responses:

- Represents time-based Restricted Stock Units (RSUs) granted on May 1, 2025. All RSUs vest in three equal annual installments, with 1/3 vesting on each of June 10, 2026, 2027, and 2028, subject to continuous service through each such Vesting Date.
- The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of May 1, 2025, subject to continuous service through each such Vesting Date.

Reporting Owners

Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Davarpanah Nicole Negar 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO, CA 92121			Chief Medical Officer	

Signatures

/s/ Shane Ward, Attorney-in-Fact

5/12/2025

**Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.